LEE'S PHARM (00950) plans to invest 25 million yuan in the Life and Health Industry Fund to lay out the biotechnology track.

On May 11, 2026, Lee's Pharm (00950) announced that its indirect fully-owned subsidiary, ZhaoKe Hefei, general partner Rui Fu Bo Jian, and other limited partners have entered into a limited partnership agreement. According to this agreement, these partners have contributed RMB 200 million to the fund, while ZhaoKe Hefei has agreed to contribute RMB 25 million to the fund, equivalent to approximately 12.5% of the fund's equity. The purpose of the fund is to seek investment opportunities in non-listed entities in the life and health, biotechnology, and related industries, aligning with the company's business strategy. Through strategic partnerships, investments, and acquisitions in the pharmaceutical field, the fund aims to strengthen its business. Investing in the fund aligns with the group's core strategy of expanding its pharmaceutical and healthcare portfolio through influential partnerships and acquisitions. By subscribing to the limited partnership interests in the fund, the group can indirectly enter into high-growth non-listed entities in the biotechnology and life sciences sector, leveraging the industry expertise of the general partner.